Literature DB >> 15788475

Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients.

David Wayne Johnson1, Carolyn van Eps, David William Mudge, Kathryn Joan Wiggins, Kirsty Armstrong, Carmel Mary Hawley, Scott Bryan Campbell, Nicole Maree Isbel, Graeme Robert Nimmo, Harry Gibbs.   

Abstract

The clinical usefulness of hemodialysis catheters is limited by increased infectious morbidity and mortality. Topical antiseptic agents, such as mupirocin, are effective at reducing this risk but have been reported to select for antibiotic-resistant strains. The aim of the present study was to determine the efficacy and the safety of exit-site application of a standardized antibacterial honey versus mupirocin in preventing catheter-associated infections. A randomized, controlled trial was performed comparing the effect of thrice-weekly exit-site application of Medihoney versus mupirocin on infection rates in patients who were receiving hemodialysis via tunneled, cuffed central venous catheters. A total of 101 patients were enrolled. The incidences of catheter-associated bacteremias in honey-treated (n = 51) and mupirocin-treated (n = 50) patients were comparable (0.97 versus 0.85 episodes per 1000 catheter-days, respectively; NS). On Cox proportional hazards model analysis, the use of honey was not significantly associated with bacteremia-free survival (unadjusted hazard ratio, 0.94; 95% confidence interval, 0.27 to 3.24; P = 0.92). No exit-site infections occurred. During the study period, 2% of staphylococcal isolates within the hospital were mupirocin resistant. Thrice-weekly application of standardized antibacterial honey to hemodialysis catheter exit sites was safe, cheap, and effective and resulted in a comparable rate of catheter-associated infection to that obtained with mupirocin (although the study was not adequately powered to assess therapeutic equivalence). The effectiveness of honey against antibiotic-resistant microorganisms and its low likelihood of selecting for further resistant strains suggest that this agent may represent a satisfactory alternative means of chemoprophylaxis in patients with central venous catheters.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788475     DOI: 10.1681/ASN.2004110997

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  30 in total

1.  A crossover intervention trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergoing hemodialysis.

Authors:  Bernard C Camins; Amy M Richmond; Kathrin L Dyer; Heather N Zimmerman; Daniel W Coyne; Marcos Rothstein; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

2.  Dialysis: Prevention of peritoneal-dialysis-related infections-antibacterial honey might not be the solution.

Authors:  Ellen F Carney
Journal:  Nat Rev Nephrol       Date:  2013-10-22       Impact factor: 28.314

Review 3.  Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.

Authors:  Bradley A Warady; Sevcan Bakkaloglu; Jason Newland; Michelle Cantwell; Enrico Verrina; Alicia Neu; Vimal Chadha; Hui-Kim Yap; Franz Schaefer
Journal:  Perit Dial Int       Date:  2012-06       Impact factor: 1.756

Review 4.  Antimicrobial strategies centered around reactive oxygen species--bactericidal antibiotics, photodynamic therapy, and beyond.

Authors:  Fatma Vatansever; Wanessa C M A de Melo; Pinar Avci; Daniela Vecchio; Magesh Sadasivam; Asheesh Gupta; Rakkiyappan Chandran; Mahdi Karimi; Nivaldo A Parizotto; Rui Yin; George P Tegos; Michael R Hamblin
Journal:  FEMS Microbiol Rev       Date:  2013-07-25       Impact factor: 16.408

5.  Reducing catheter-related infections in hemodialysis patients.

Authors:  Daniel Landry; Gregory Braden
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 8.237

Review 6.  Wound care with antibacterial honey (Medihoney) in pediatric hematology-oncology.

Authors:  Arne Simon; Kai Sofka; Gertrud Wiszniewsky; Gisela Blaser; Udo Bode; Gudrun Fleischhack
Journal:  Support Care Cancer       Date:  2005-08-02       Impact factor: 3.603

7.  Antibacterial honey (Medihoney) for wound care of immunocompromised pediatric oncology patients.

Authors:  Arne Simon; Kai Sofka; Gertrud Wieszniewsky; Gisela Blaser
Journal:  GMS Krankenhhyg Interdiszip       Date:  2006-08-30

8.  The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial.

Authors:  Lei Zhang; Sunil V Badve; Elaine M Pascoe; Elaine Beller; Alan Cass; Carolyn Clark; Janak de Zoysa; Nicole M Isbel; Steven McTaggart; Alicia T Morrish; E Geoffrey Playford; Anish Scaria; Paul Snelling; Liza A Vergara; Carmel M Hawley; David W Johnson
Journal:  Perit Dial Int       Date:  2015-07-29       Impact factor: 1.756

9.  Central venous catheter-associated bloodstream infections in hemodialysis patients: Another patient safety bundle?

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-03       Impact factor: 2.471

10.  Rationale and design of the HEALTHY-CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients.

Authors:  Jennifer K Broom; Stacey O'Shea; Sridevi Govindarajulu; E Geoffrey Playford; Carmel M Hawley; Nicole M Isbel; Scott B Campbell; David W Mudge; Sally Carpenter; Barbara C Johnson; Neil P Underwood; David W Johnson
Journal:  BMC Nephrol       Date:  2009-08-20       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.